New targets for overactive bladder-ICI-RS 2109.
TRP channels
cyclic nucleotides
fibrosis
small conductance K+ channels
β3-agonists
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
14
09
2019
accepted:
31
10
2019
pubmed:
19
11
2019
medline:
22
12
2020
entrez:
19
11
2019
Statut:
ppublish
Résumé
To review evidence for novel drug targets that can manage overactive bladder (OAB) symptoms. A think tank considered evidence from the literature and their own research experience to propose new drug targets in the urinary bladder to characterize their use to treat OAB. Five classes of agents or cellular pathways were considered. (a) Cyclic nucleotide-dependent (cyclic adenosine monophosphate and cyclic guanosine monophosphate) pathways that modulate adenosine triphosphate release from motor nerves and urothelium. (b) Novel targets for β The specificity of action remains a consideration if particular classes of agents can be considered for future development as receptors or pathways that mediate actions of the above mentioned potential agents are distributed among most organ systems. The tasks are to determine more detail of the pathological changes that occur in the OAB and how the specificity of potential drugs may be directed to bladder pathological changes. An important conclusion was that the storage, not the voiding, phase in the micturition cycle should be investigated and potential targets lie in the whole range of tissue in the bladder wall and not just detrusor.
Identifiants
pubmed: 31737931
doi: 10.1002/nau.24228
pmc: PMC8114459
mid: NIHMS1699942
doi:
Substances chimiques
Urological Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S113-S121Subventions
Organisme : Medical Research Council
ID : MR/M012425/1
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : R01 DK098361
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Am J Physiol Cell Physiol. 2011 Oct;301(4):C903-12
pubmed: 21697543
Br J Pharmacol. 2017 May;174(10):962-976
pubmed: 27250825
Front Physiol. 2014 Oct 09;5:389
pubmed: 25346695
Curr Opin Pharmacol. 2015 Apr;21:95-104
pubmed: 25645316
J Physiol. 2018 Aug;596(16):3531-3552
pubmed: 29873405
Naunyn Schmiedebergs Arch Pharmacol. 2018 Nov;391(11):1191-1202
pubmed: 30054681
Am J Physiol Regul Integr Comp Physiol. 2001 Nov;281(5):R1699-709
pubmed: 11641143
BJU Int. 2011 Aug;108(4):604-11
pubmed: 21166758
Low Urin Tract Symptoms. 2019 Apr;11(2):O209-O217
pubmed: 30632283
Pharmacol Ther. 2016 Mar;159:66-82
pubmed: 26808167
Front Physiol. 2015 Apr 23;6:114
pubmed: 25954203
J Pharmacol Exp Ther. 2015 Sep;354(3):290-301
pubmed: 26087697
Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):127-137
pubmed: 27761601
Vascul Pharmacol. 2014 Feb;60(2):84-94
pubmed: 24418022
Br J Pharmacol. 2019 Jul;176(13):2227-2237
pubmed: 30924527
Am J Physiol Regul Integr Comp Physiol. 2014 Sep 15;307(6):R571-84
pubmed: 24990859
Br J Pharmacol. 2010 Jul;160(5):1135-43
pubmed: 20590607
Am J Physiol Renal Physiol. 2014 May 15;306(10):F1121-35
pubmed: 24647709
BJU Int. 2005 May;95(7):1002-5
pubmed: 15839921
J Pharmacol Exp Ther. 2014 Nov;351(2):259-69
pubmed: 25125580
Nat Rev Urol. 2011 Dec 13;9(1):30-40
pubmed: 22158596
J Pediatr Urol. 2019 Apr;15(2):154.e1-154.e9
pubmed: 30745011
Cell Tissue Res. 2020 Feb;379(2):373-387
pubmed: 31446446
Med Sci (Basel). 2019 May 22;7(5):
pubmed: 31121962
Am J Physiol Cell Physiol. 2016 Apr 1;310(7):C600-11
pubmed: 26791488
Neurourol Urodyn. 2018 Jun;37(S4):S7-S12
pubmed: 30133788
J Physiol. 2018 Aug;596(16):3493-3503
pubmed: 29781524
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Lancet. 2015 Mar 28;385(9974):1198-205
pubmed: 25467586
Neurourol Urodyn. 2015 Nov;34(8):787-93
pubmed: 25230878
J Urol. 2014 Feb;191(2):539-47
pubmed: 24050894
Scand J Urol Nephrol Suppl. 1999;201:25-31
pubmed: 10573773
Neurourol Urodyn. 2017 Nov;36(8):1972-1980
pubmed: 28185314
Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F817-F821
pubmed: 27440781
Eur Urol. 1999;36 Suppl 1:23-30
pubmed: 10393469
J Urol. 2007 Mar;177(3):1071-7
pubmed: 17296414
Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15;304(2):R155-63
pubmed: 23174857
J Gen Physiol. 2016 Apr;147(4):323-35
pubmed: 26976828
Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F388-F403
pubmed: 28446460
Am J Physiol Cell Physiol. 2019 Jul 1;317(1):C131-C142
pubmed: 31042424
ScientificWorldJournal. 2009 Aug 31;9:846-54
pubmed: 20333343
Nat Med. 2016 Oct;22(10):1151-1159
pubmed: 27595323
J Urol. 2016 Oct;196(4):1287-94
pubmed: 27157371
J Urol. 2001 Jan;165(1):240-4
pubmed: 11125417
J Pharmacol Exp Ther. 1999 Mar;288(3):1367-73
pubmed: 10027879
Br J Pharmacol. 2017 May;174(10):950-961
pubmed: 27922185
BMC Urol. 2006 Mar 06;6:6
pubmed: 16519806
Br J Pharmacol. 2009 Jun;157(4):607-19
pubmed: 19371347
Neurourol Urodyn. 2018 Nov;37(8):2441-2451
pubmed: 29806709
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9
pubmed: 20956320
Low Urin Tract Symptoms. 2019 Sep;11(4):177-181
pubmed: 30900373
Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R471-80
pubmed: 24965792
J Biol Chem. 2004 Aug 27;279(35):36746-52
pubmed: 15184377
Naunyn Schmiedebergs Arch Pharmacol. 2016 Aug;389(8):921-9
pubmed: 27185496
Basic Clin Pharmacol Toxicol. 2016 Oct;119 Suppl 3:75-85
pubmed: 26990140
BJU Int. 2013 Mar;111(3):505-13
pubmed: 22882496
Urology. 2006 Aug;68(2):442-8
pubmed: 16904481
Adv Exp Med Biol. 2019;1124:121-147
pubmed: 31183825
Eur J Pharmacol. 2015 Jul 5;758:115-22
pubmed: 25861936
Eur Urol. 2019 Jun;75(6):988-1000
pubmed: 30922690
J Urol. 2009 May;181(5):2355-65
pubmed: 19303094
Acta Physiol (Oxf). 2013 Jan;207(1):7-15
pubmed: 23034074
Br J Pharmacol. 1992 Jun;106(2):416-22
pubmed: 1393268